Overview

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm, phase I study of irinotecan liposome injection in patients with advanced breast cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan liposome injection in patients with advanced breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Irinotecan